Mechanisms of broadly neutralizing humoral immunity against influenza viruses

  • Palese, Peter (PI)
  • Ravetch, Jeffrey Victor (CoPI)
  • Wilson, Patrick Christopher (CoPI)

Project Details


DESCRIPTION (provided by applicant): Human vaccines have most often been generated by trial and error with little understanding of molecular mechanisms involved in the protective immunity that they provide. This system of vaccine development has been remarkably effective against pathogens that exhibit little variability over time; however, it has become evident that a much more sophisticated approach is required to develop broadly protective vaccines against pathogens that undergo continuous structural change, such as influenza viruses. Current influenza virus vaccines confer protection by eliciting antibodies that block viral entry by bindin regions of the virus that are highly mutable. In order for antibody-based therapies and vaccines to be effective against a breadth of structurally diverse influenza viruses, protection will clearl have to be gained through alternate routes of blocking viral replication. The identification of broadly neutralizing monoclonal antibodies against the conserved stalk domain of the viral hemagglutinin (HA), by members of our group and by others, was a groundbreaking advance, as many of these antibodies are able to block fusion of viral and endosomal membranes, yet bind epitopes that are relatively resistant to structural change. A second critical finding by members of our group was that protection mediated by anti-stalk antibodies at low concentrations is dependent on Fc-Fc Receptor (FcR) interactions; therefore, antibody isotype determines protective activity of anti-stalk antibodies at lower concentrations. The current proposal is for a multi-center investigation into molecular mechanisms that can be harnessed to provide broad-based protection against influenza viruses. Our projects include: 1) Precise mapping of epitopes on the viral HA and neuraminidase glycoproteins that mediate virus neutralization, and dissection of mechanisms by which they achieve neutralization. 2) Immunization studies using chimeric influenza virus proteins designed to identify structural elements able to mediate broad-spectrum humoral immunity. 3) Delineation of the roles of Fc-FcR interactions in viral neutralization. 4) Investigation in human subjects into how to elicit antibodies with favorable Fc domains during vaccination. 5) Studies on the natural evolution of human B cell specificities against influenza antigens. 6) Identification of specific sequences of influenza antigen exposures that elicit broad-spectrum, anti-influenza humoral immunity. Overall, our intention is to better understand the mechanisms of broadly protective humoral immune responses against the influenza virus surface proteins and thereby create a blueprint for advancing a new generation of broadly protective influenza virus vaccines and antibody-based therapeutics.
Effective start/end date1/04/1431/03/19


  • National Institute of Allergy and Infectious Diseases: $1,953,101.00
  • National Institute of Allergy and Infectious Diseases: $1,918,351.00
  • National Institute of Allergy and Infectious Diseases: $1,918,351.00
  • National Institute of Allergy and Infectious Diseases: $1,918,351.00
  • National Institute of Allergy and Infectious Diseases: $1,918,351.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.